Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Frontiers in immunology · 2024
Review
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 2 countries.
Sarita Rani JaiswalCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi 110096, India.
Ashraf SaifullahDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi 110096, India.
Jaganath ArunachalamCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi 110096, India.
Rohit LakhchauraDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi 110096, India.
Dhanir TailorDepartment of Cell, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Anupama MehtaDepartment of Blood and Marrow Transplantation, Dharamshila Narayana Super-Speciality Hospital, New Delhi 110096, India.
Gitali BhagawatiDepartment of Pathology and Microbiology, Dharamshila Narayana Super-Speciality Hospital, New Delhi 110096, India.
Hemamalini AiyerDepartment of Pathology and Microbiology, Dharamshila Narayana Super-Speciality Hospital, New Delhi 110096, India.
Subhrajit BiswasAmity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida 201313, India.ORCID 0000-0001-5649-364X
Sanjay V MalhotraDepartment of Cell, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0003-4056-5033
Suparno ChakrabartiCellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi 110096, India.ORCID 0000-0003-1642-5065
Amity University · INOregon Health & Science University · USCadila Pharmaceuticals (India) · IN
Funding
Indo-US Science and Technology Forum IUSSTF/VN-COVID/049/2020
6 · The paper itself
Abstract
Mycobacterium-
Indexed as
ADCCChAdOx1 nCoV-19COVID-19innate immunityMycobacterium w (Mw)SARS-CoV-2
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Augmenting Vaccine Efficacy against Delta Variant with 'Mycobacterium- · full record | OpenQuestion